https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-05 / Cells 2020 Jun;9(6)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-05 / Cells 2020 Jun;9(6)2020-06-05 00:00:002020-06-05 00:00:00Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-05-13 / Hum Vaccin Immunother 2020 May;:1-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-05-13 / Hum Vaccin Immunother 2020 May;:1-92020-05-13 00:00:002020-05-13 00:00:00Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-16 / NPJ Vaccines 2020;5:5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-16 / NPJ Vaccines 2020;5:52020-01-16 00:00:002020-08-26 13:53:37Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-09-01 / J. Neurosurg. 2019 09;131(3):657-666
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-09-01 / J. Neurosurg. 2019 09;131(3):657-6662019-09-01 00:00:002019-09-01 00:00:00The current state of immunotherapy for gliomas: an eye toward the future
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-08-09 / J Extracell Vesicles 2019;8(1):1648995
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-08-09 / J Extracell Vesicles 2019;8(1):16489952019-08-09 00:00:002020-08-31 08:17:52Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-17 / J Clin Oncol 37, 2019 (suppl; abstr e13526)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-17 / J Clin Oncol 37, 2019 (suppl; abstr e13526)2019-06-17 11:50:402019-07-17 11:53:03Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-04-15 / Cancers (Basel) 2019 Apr;11(4)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-04-15 / Cancers (Basel) 2019 Apr;11(4)2019-04-15 00:00:002019-04-15 00:00:00A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-04-01 / Anticancer Res 2019 Apr;39(4):2043-2051
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-04-01 / Anticancer Res 2019 Apr;39(4):2043-20512019-04-01 00:00:002021-11-15 20:00:34Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-01-07 / Int. J. Cancer 2019 Jun;144(11):2867-2879
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-01-07 / Int. J. Cancer 2019 Jun;144(11):2867-28792019-01-07 00:00:002019-01-07 00:00:00An effective dendritic cell-based vaccine containing glioma stem-like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-01-01 / Klin Onkol 2019;32(1):70-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-01-01 / Klin Onkol 2019;32(1):70-742019-01-01 00:00:002019-01-01 00:00:00Effective Immunotherapy of Glioblastoma in an Adolescent with Constitutional Mismatch Repair-Deficiency Syndrome
